Constellation Pharmaceuticals

OverviewSuggest Edit

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops novel drugs that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Its integrated epigenetics platform helps to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity.

TypePublic
Founded2008
HQCambridge, MA, US
Websiteconstellationpharma.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Feb 2019)82(+29%)
Job Openings8
Share Price (Jul 2021)$34
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Constellation Pharmaceuticals

Jigar Raythatha

Jigar Raythatha

President, Chief Executive Officer
Barbara Krebs-Pohl

Barbara Krebs-Pohl

Chief Integration Officer
Mark A. Goldsmith

Mark A. Goldsmith

Executive Chairman
Jeffrey Humphrey

Jeffrey Humphrey

Chief Medical Officer
Patrick Trojer

Patrick Trojer

Chief Scientific Officer
Mohan Bala

Mohan Bala

Chief Operating Officer
Show more

Constellation Pharmaceuticals Office Locations

Constellation Pharmaceuticals has offices in Cambridge and Boston
Cambridge, MA, US (HQ)
215 First St
Boston, MA, US
470 Atlantic Ave 14th Floor
Show all (2)

Constellation Pharmaceuticals Financials and Metrics

Constellation Pharmaceuticals Revenue

USD

Net income (Q1, 2018)

(12.1m)

EBIT (Q1, 2018)

(12.2m)

Market capitalization (21-Jul-2021)

1.6b

Closing stock price (21-Jul-2021)

34.0

Cash (31-Mar-2018)

71.5m

EV

1.6b
Constellation Pharmaceuticals's current market capitalization is $1.6 b.
Annual
USDFY, 2016FY, 2017

General and administrative expense

5.8m6.5m

R&D expense

27.9m32.6m

Operating expense total

33.7m39.1m

EBIT

(33.7m)(39.1m)
Quarterly
USDQ1, 2017Q1, 2018

General and administrative expense

1.2m2.3m

R&D expense

6.9m9.9m

Operating expense total

8.0m12.2m

EBIT

(8.0m)(12.2m)
Annual
USDFY, 2016FY, 2017

Cash

36.9m16.4m

Prepaid Expenses

515.0k1.3m

Current Assets

37.4m17.7m

PP&E

1.0m1.1m
Quarterly
USDQ1, 2018

Cash

71.5m

Prepaid Expenses

1.9m

Current Assets

73.4m

PP&E

1.0m
Annual
USDFY, 2016FY, 2017

Net Income

(34.5m)(35.4m)

Depreciation and Amortization

203.0k474.0k

Accounts Payable

423.0k67.0k

Cash From Operating Activities

(32.8m)(37.6m)
Quarterly
USDQ1, 2017Q1, 2018

Net Income

(5.7m)(12.1m)

Depreciation and Amortization

98.0k135.0k

Accounts Payable

(1.3m)562.0k

Cash From Operating Activities

(11.4m)(11.8m)
USDFY, 2016

Financial Leverage

-0.3 x
Show all financial metrics

Constellation Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Constellation Securities Corporation

Constellation Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Constellation Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Constellation Pharmaceuticals Online and Social Media Presence

Embed Graph

Constellation Pharmaceuticals News and Updates

Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib

CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to the MANIFEST clinical tri…

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Constellation Pharmaceuticals, Inc. - CNST

NEW YORK, June 4, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...

Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today summarized in a poster presentation preliminary data from the ongo…

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Constellation Pharmaceuticals, Inc. Buyout

WILMINGTON, Del., June 02, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Constellation Pharmaceuticals, Inc. (“Constellation”) (NASDAQ GS: CNST) regarding possible breaches of fiduciary duties and other violations of law related to Constellation’s agreement to be …

Thinking about buying stock in Constellation Pharmaceuticals, Neovasc, Orbital Energy, Washington Prime Group, or Urban One?

NEW YORK, June 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNST, NVCN, OEG, WPG, and UONE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual …
Show more

Constellation Pharmaceuticals Blogs

The JMP Securities Life Sciences Conference (New York City)

The JMP Securities Life Sciences Conference (New York City) Altinger-RalleI Fri, 04/29/2022 - 12:17 In Person Thu, 06/16/2022 - 12:16 Thu, 06/16/2022 - 12:16

J.P. Morgan European Healthcare Conference (London)

J.P. Morgan European Healthcare Conference (London) Altinger-RalleI Fri, 04/29/2022 - 12:15 In Person Thu, 06/23/2022 - 12:10 Thu, 06/23/2022 - 12:10

14th Kempen Life Sciences Conference (Amsterdam)

14th Kempen Life Sciences Conference (Amsterdam) danilo.brandt Fri, 02/04/2022 - 17:18 Virtual Thu, 04/21/2022 - 09:00 Thu, 04/21/2022 - 18:00

SVB Leerink 11th Annual Global Healthcare Conference

SVB Leerink 11th Annual Global Healthcare Conference danilo.brandt Fri, 02/04/2022 - 17:14 Virtual Thu, 02/17/2022 - 09:00 Thu, 02/17/2022 - 18:00

Third Quarter Interim Statement 2022

Third Quarter Interim Statement 2022 GruentgensM Mon, 01/17/2022 - 13:50 Virtual Wed, 11/16/2022 - 12:00 Wed, 11/16/2022 - 23:59

Half-Year Report 2022

Half-Year Report 2022 GruentgensM Mon, 01/17/2022 - 13:50 Virtual Wed, 08/03/2022 - 12:00 Wed, 08/03/2022 - 23:59
Show more

Constellation Pharmaceuticals Frequently Asked Questions

  • When was Constellation Pharmaceuticals founded?

    Constellation Pharmaceuticals was founded in 2008.

  • Who are Constellation Pharmaceuticals key executives?

    Constellation Pharmaceuticals's key executives are Jigar Raythatha, Barbara Krebs-Pohl and Mark A. Goldsmith.

  • How many employees does Constellation Pharmaceuticals have?

    Constellation Pharmaceuticals has 82 employees.

  • Who are Constellation Pharmaceuticals competitors?

    Competitors of Constellation Pharmaceuticals include Imago BioSciences, Omega Therapeutics and Moderna.

  • Where is Constellation Pharmaceuticals headquarters?

    Constellation Pharmaceuticals headquarters is located at 215 First St, Cambridge.

  • Where are Constellation Pharmaceuticals offices?

    Constellation Pharmaceuticals has offices in Cambridge and Boston.

  • How many offices does Constellation Pharmaceuticals have?

    Constellation Pharmaceuticals has 2 offices.